Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative IMRT plus capecitabine for locally advanced rectal cancer
ChiCTR-ONC-13004082Phase 2Completed
- Sponsor
- Jinhua Hospital of Zhejiang University
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in rectal cancer, sponsored by Jinhua Hospital of Zhejiang University. Primary endpoints: Toxicity during chemoradiation, Pathological downstaging rate and 3 more. Started Jan 2014; status: completed.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR-ONC-13004082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-13004082.